Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.36
CBM's Cash to Debt is ranked higher than
51% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. CBM: 0.36 )
CBM' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 0.36

Equity to Asset 0.48
CBM's Equity to Asset is ranked higher than
60% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CBM: 0.48 )
CBM' s 10-Year Equity to Asset Range
Min: 0.22   Max: 0.74
Current: 0.48

0.22
0.74
F-Score: 4
Z-Score: 3.23
M-Score: -2.48
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 15.60
CBM's Operating margin (%) is ranked higher than
90% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. CBM: 15.60 )
CBM' s 10-Year Operating margin (%) Range
Min: -2.77   Max: 18.02
Current: 15.6

-2.77
18.02
Net-margin (%) 8.14
CBM's Net-margin (%) is ranked higher than
86% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. CBM: 8.14 )
CBM' s 10-Year Net-margin (%) Range
Min: -98.33   Max: 82.87
Current: 8.14

-98.33
82.87
ROE (%) 12.33
CBM's ROE (%) is ranked higher than
91% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -20.60 vs. CBM: 12.33 )
CBM' s 10-Year ROE (%) Range
Min: -93.72   Max: 205.03
Current: 12.33

-93.72
205.03
ROA (%) 5.66
CBM's ROA (%) is ranked higher than
90% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. CBM: 5.66 )
CBM' s 10-Year ROA (%) Range
Min: -38.12   Max: 56.03
Current: 5.66

-38.12
56.03
ROC (Joel Greenblatt) (%) 19.50
CBM's ROC (Joel Greenblatt) (%) is ranked higher than
90% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -243.56 vs. CBM: 19.50 )
CBM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3.56   Max: 19.9
Current: 19.5

-3.56
19.9
Revenue Growth (%) 10.20
CBM's Revenue Growth (%) is ranked higher than
84% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. CBM: 10.20 )
CBM' s 10-Year Revenue Growth (%) Range
Min: -17.6   Max: 10.2
Current: 10.2

-17.6
10.2
EBITDA Growth (%) 17.70
CBM's EBITDA Growth (%) is ranked higher than
91% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. CBM: 17.70 )
CBM' s 10-Year EBITDA Growth (%) Range
Min: -27   Max: 32.8
Current: 17.7

-27
32.8
EPS Growth (%) 45.20
CBM's EPS Growth (%) is ranked higher than
97% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. CBM: 45.20 )
CBM' s 10-Year EPS Growth (%) Range
Min: -82.6   Max: 79.7
Current: 45.2

-82.6
79.7
» CBM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

CBM Guru Trades in Q2 2013

Jim Simons 723,500 sh (+7.71%)
Paul Tudor Jones Sold Out
Chuck Royce 1,320,494 sh (-7.05%)
Steven Cohen 15,148 sh (-34.37%)
» More
Q3 2013

CBM Guru Trades in Q3 2013

Paul Tudor Jones 46,100 sh (New)
Steven Cohen 22,521 sh (+48.67%)
Jim Simons 935,800 sh (+29.34%)
Chuck Royce 1,423,932 sh (+7.83%)
» More
Q4 2013

CBM Guru Trades in Q4 2013

Chuck Royce 1,526,854 sh (+7.23%)
Steven Cohen Sold Out
Jim Simons 633,600 sh (-32.29%)
Paul Tudor Jones 19,403 sh (-57.91%)
» More
Q1 2014

CBM Guru Trades in Q1 2014

Paul Tudor Jones 18,500 sh (-4.65%)
Jim Simons 470,525 sh (-25.74%)
Chuck Royce 951,854 sh (-37.66%)
» More
» Details

Insider Trades

Latest Guru Trades with CBM

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-03-31 Sold Out 0.09%$11.27 - $12.79 $ 22.0885%0
Joel Greenblatt 2012-12-31 New Buy0.09%$9.34 - $13.96 $ 22.0894%142352
Joel Greenblatt 2012-09-30 Sold Out 0.02%$9.01 - $13.01 $ 22.08100%0
Joel Greenblatt 2012-06-30 New Buy0.02%$5.96 - $9.16 $ 22.08212%30208
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 43.50
CBM's P/E(ttm) is ranked higher than
90% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBM: 43.50 )
CBM' s 10-Year P/E(ttm) Range
Min: 1.05   Max: 63.2
Current: 43.5

1.05
63.2
P/B 3.20
CBM's P/B is ranked higher than
84% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 5.51 vs. CBM: 3.20 )
CBM' s 10-Year P/B Range
Min: 0.61   Max: 5.22
Current: 3.2

0.61
5.22
P/S 2.22
CBM's P/S is ranked higher than
94% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 19.16 vs. CBM: 2.22 )
CBM' s 10-Year P/S Range
Min: 0.18   Max: 10.71
Current: 2.22

0.18
10.71
EV-to-EBIT 16.47
CBM's EV-to-EBIT is ranked higher than
95% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBM: 16.47 )
CBM' s 10-Year EV-to-EBIT Range
Min: 6.7   Max: 388.4
Current: 16.47

6.7
388.4
PEG 3.20
CBM's PEG is ranked higher than
95% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBM: 3.20 )
CBM' s 10-Year PEG Range
Min: 0.52   Max: 42.7
Current: 3.2

0.52
42.7
Shiller P/E 31.00
CBM's Shiller P/E is ranked higher than
97% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBM: 31.00 )
CBM' s 10-Year Shiller P/E Range
Min: 5.61   Max: 141.6
Current: 31

5.61
141.6
Current Ratio 1.98
CBM's Current Ratio is ranked higher than
58% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. CBM: 1.98 )
CBM' s 10-Year Current Ratio Range
Min: 0.9   Max: 5.19
Current: 1.98

0.9
5.19
Quick Ratio 0.91
CBM's Quick Ratio is ranked higher than
52% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. CBM: 0.91 )
CBM' s 10-Year Quick Ratio Range
Min: 0.5   Max: 4.55
Current: 0.91

0.5
4.55

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 4.00
CBM's Price/Tangible Book is ranked higher than
85% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 8.78 vs. CBM: 4.00 )
CBM' s 10-Year Price/Tangible Book Range
Min: 1.63   Max: 14.41
Current: 4

1.63
14.41
Price/DCF (Projected) 2.40
CBM's Price/DCF (Projected) is ranked higher than
96% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBM: 2.40 )
CBM' s 10-Year Price/DCF (Projected) Range
Min: 0.83   Max: 12.66
Current: 2.4

0.83
12.66
Price/Median PS Value 1.80
CBM's Price/Median PS Value is ranked higher than
73% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. CBM: 1.80 )
CBM' s 10-Year Price/Median PS Value Range
Min: 0.21   Max: 7.42
Current: 1.8

0.21
7.42
Price/Peter Lynch Fair Value 3.40
CBM's Price/Peter Lynch Fair Value is ranked higher than
97% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBM: 3.40 )
CBM' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.56   Max: 8.25
Current: 3.4

0.56
8.25
Price/Graham Number 2.40
CBM's Price/Graham Number is ranked higher than
94% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBM: 2.40 )
CBM' s 10-Year Price/Graham Number Range
Min: 0.43   Max: 4.95
Current: 2.4

0.43
4.95
Earnings Yield (Greenblatt) 6.00
CBM's Earnings Yield (Greenblatt) is ranked higher than
73% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. CBM: 6.00 )
CBM' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 14.9
Current: 6

0.3
14.9
Forward Rate of Return (Yacktman) 11.43
CBM's Forward Rate of Return (Yacktman) is ranked higher than
93% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: -10.54 vs. CBM: 11.43 )
CBM' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -29   Max: 19.9
Current: 11.43

-29
19.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:XBX.Germany
Cambrex Corporation was incorporated in a Delaware, began business in December 1981. Cambrex is a life sciences Company dedicated to providing products and services that accelerate and improve the discovery and commercialization of human therapeutics. The Company mainly supplies its products and services worldwide to pharmaceutical and generic drug companies. Cambrex has three operating segments, which are manufacturing facilities that have been aggregated as one reportable segment. The Company's overall strategy is to: grow its portfolio of custom development projects, especially those in the later stages of the clinical trial process, secure long-term supply agreements to produce active pharmaceutical ingredients ("APIs") and intermediates for newly approved drug products; expand sales of products and projects based on its proprietary technologies; and partner with generic drug companies to grow the Company's portfolio of generic APIs. The Company participates in markets that serve the healthcare industry. Customers include companies that discover and commercialize new small molecule human therapeutics using organic chemistry and generic drug companies. The Company's business is mainly comprised of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. Products and services are supplied globally to innovative and generic drug companies. Products include APIs and advanced pharmaceutical intermediates. Services include custom development and current Good Manufacturing Practices ("cGMP") manufacturing services. The Company has at least 25 mainly API and advanced intermediate competitors throughout Western Europe and the U.S. and many more competitors within different segments of the markets the Company serves, including a growing number of competitors in Asia, Eastern Europe and other low-cost areas. The Company's operations are subject to laws and regulations relating to the storage, handling, emission, transportation and discharge of materials into the environment and the maintenance of safe working conditions.
» More Articles for CBM

Headlines

Articles On GuruFocus.com
Cambrex Corp. Reports Operating Results (10-Q) Aug 04 2010 
Cambrex Corp. Reports Operating Results (10-Q) May 05 2010 
Does Cambrex Corporation Have Earnings Persistence? Apr 28 2010 
Cambrex Corp. Reports Operating Results (10-Q) Nov 04 2009 

More From Other Websites
NYSE stocks posting largest volume increases Jul 25 2014
Cambrex Manufacturing Facility Completes Successful US FDA Pre-Approval Inspection Jul 12 2014
Cambrex Manufacturing Facility Completes Successful US FDA Inspection Jul 12 2014
NeoStem Appoints Steven M. Klosk to Board of Directors Jul 08 2014
NeoStem Appoints Steven M. Klosk to Board of Directors Jul 08 2014
CAMBREX CORP Files SEC form 8-K, Change in Directors or Principal Officers May 29 2014
James F. Winschel Appointed to the Board of Directors of Cambrex Corporation May 29 2014
Cambrex To Present At Upcoming Investor Conferences In June May 23 2014
Largest option trades in equities May 22 2014
Stephen Hertz, Debevoise M&A Lawyer, Dies at 55 in Building Leap May 20 2014
Cambrex To Present At UBS Global Healthcare Conference May 12 2014
CAMBREX CORP Financials May 09 2014
Cambrex Corporation's CEO Discusses Q1 2014 Results - Earnings Call Transcript May 02 2014
Cambrex Earnings Call scheduled for 8:30 am ET today May 02 2014
Cambrex Corporation Discusses Q1 2014 Results (Webcast) May 02 2014
CAMBREX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 02 2014
Q1 2014 Cambrex Earnings Release - Before Market Open May 02 2014
Cambrex Reports First Quarter 2014 Financial Results May 02 2014
Cambrex To Announce First Quarter 2014 Financial Results On May 2, 2014 Apr 28 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide